Cart
sales@molnova.com
Sesamol
CAS No. 533-31-3
Sesamol ( —— )
Catalog No. M18752 CAS No. 533-31-3
Sesamol could decrease lung inflammation and lipopolysaccharide (LPS)-induced lung injury in rats.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | 26 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSesamol
-
NoteResearch use only, not for human use.
-
Brief DescriptionSesamol could decrease lung inflammation and lipopolysaccharide (LPS)-induced lung injury in rats.
-
DescriptionSesamol could decrease lung inflammation and lipopolysaccharide (LPS)-induced lung injury in rats. Sesamol ameliorates inflammatory and oxidative damage by upregulating AMPK activation and Nrf2 signaling and blocking the NF-κB and MAPK signaling pathways and inhibits melanin biosynthesis by down-regulating tyrosinase activity and melanin production via regulation of gene expression of melanogenesis-related proteins through modulation of MITF activity, which promotes phosphorylation of p38 and JNK in melan-a cells.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAMPK
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number533-31-3
-
Formula Weight138.12
-
Molecular FormulaC7H6O3
-
Purity98%
-
Solubility——
-
SMILESC1Oc2c(O1)cc(cc2)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wu XL, et al. Inflamm Res. 2015 Aug;64(8):577-88.
molnova catalog
related products
-
Notoginsenoside L13
Reference standards.
-
BDC2.5 mimotope 1040...
This is a effectively agonistic peptide (mimotope) for diabetogenic T cell clone BDC2.5. It can stimulate BDC2.5 cells with cells showing good response to this mimotope. 1040-31 peptide is specific for BDC2.5 TCR Tg+ (transgenic) T cells. This peptide is also known as p31.
-
Phytolaccagenin
Phytolaccagenin, a triterpenoid saponin, is the active component of Radix Phtolaccae which are widely used in East Asian countries for the treatment of inflammation-related diseases.
